Recurrent Glioblastoma, IDH-Wildtype Clinical Trials in Los Angeles, California
2 recruitingLos Angeles, California
Showing 1–2 of 2 trials
Recruiting
Phase 1
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
GlioblastomaGlioblastoma, IDH-wildtypeRecurrent Glioblastoma, IDH-Wildtype+3 more
Jonsson Comprehensive Cancer Center50 enrolled2 locationsNCT07089641
Recruiting
Phase 1Phase 2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-WildtypeRecurrent MGMT-Methylated Glioblastoma
National Cancer Institute (NCI)97 enrolled36 locationsNCT05432804